Prothena has finished converting itself from a high-burn, wholly owned late-stage shop into a partner-funded protein-dysregulation platform. After last year's birtamimab miss in AL amyloidosis, Roche, Novo Nordisk, and Bristol Myers Squibb now carry the expensive trials. The remaining debate is whether the market treats that optionality as leftover cash or as a real pipeline. Mid-year cash still covers the compressed cost base several times over, and the board is returning capital rather than rebuilding an internal Phase 3 franchise.
The cost reset is the quarter's operating story. Research spending fell to $9 million from $41 million a year earlier as internal programs were wound down. A first-half Novo Nordisk enrollment milestone of $50 million flipped the six-month P&L into a small profit. Cash and restricted cash stood at $289 million with no funded debt. That pile is large relative to the enterprise, and the board used part of it to repurchase more than two million shares in the first half.
The next year resolves a narrower question than the late-decade Phase 3 clocks. Bristol Myers Squibb decides whether to advance PRX019 by year-end. That choice either adds a $55 million milestone or confirms the partner is walking away from the second neuroscience option. Does the equity remain a cash-backed call on those partnered readouts, or does the repurchase program become the entire story?